Recently, a meta-analysis by Lee et al. [37] had examined the role iron therapy for IBD, by comparing oral to IV therapy and concluded, similarly to our findings, that IV iron is superior to oral therapy in achieving an increase in Hb value and reduced risk of discontinuation. Here, GSTM1 is linked to inflammatory bowel disease.